HRT Financial’s Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant IBER.U Stock Holding History

HRT Financial’s Portfolio IBER.U Stock Details IBER.U Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-64,980	Closed	-$649K	–	3551
2022 Q4	$649K	Hold	64,980	–	–	0.01%	1241
2022 Q3	$644K	Hold	64,980	–	–	0.01%	1280
2022 Q2	$638K	Hold	64,980	–	–	0.01%	1315
2022 Q1	$641K	Hold	64,980	–	–	﹤0.01%	1451
2021 Q4	$651K	Hold	64,980	–	–	﹤0.01%	1559
2021 Q3	$649K	Hold	64,980	–	–	﹤0.01%	1758
2021 Q2	$653K	Hold	64,980	–	–	0.01%	1535
2021 Q1	$640K	Buy	+64,980	New	+$650K	0.01%	1591

HRT Financial's IBER.U Position: Q1 2023 in Review

HRT Financial sold out of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) in Q1 2023, closing a stake of 64,980 shares — an estimated $649K sold.

HRT Financial first reported a position in IBER.U in Q1 2021 and held it in 8 quarters. The position peaked at $653K in Q2 2021. 0 funds tracked by Wall St. Rank hold IBER.U as of Q1 2023.

HRT Financial reported no remaining Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position as of Q1 2023 after selling out during the quarter.
HRT Financial sold 64,980 Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant shares in Q1 2023, an estimated $649K.
HRT Financial first reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in Q1 2021 and held it in 8 quarters.
HRT Financial's Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position peaked at $653K in Q2 2021.
0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant as of Q1 2023.

Based on HRT Financial's 13F filing for Q1 2023, filed 12 May 2023.